Primecap Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.44B | Sell |
24,923,900
-61,249
| -0.2% | -$3.52M | 0.85% | 25 |
|
|
2026
Q1 | $1.52B | Buy |
24,985,149
+109,599
| +0.4% | +$6.39M | 1.19% | 24 |
|
|
2025
Q4 | $1.34B | Buy |
24,875,550
+2,781,230
| +13% | +$134M | 1.02% | 29 |
|
|
2025
Q3 | $996M | Sell |
22,094,320
-850,330
| -4% | -$39.7M | 0.76% | 41 |
|
|
2025
Q2 | $1.06B | Sell |
22,944,650
-25,983
| -0.1% | -$1.28M | 0.84% | 36 |
|
|
2025
Q1 | $1.4B | Buy |
22,970,633
+197,453
| +0.9% | +$11.5M | 1.16% | 24 |
|
|
2024
Q4 | $1.29B | Sell |
22,773,180
-596,390
| -3% | -$33.3M | 1% | 30 |
|
|
2024
Q3 | $1.21B | Sell |
23,369,570
-129,034
| -0.5% | -$6.05M | 0.89% | 33 |
|
|
2024
Q2 | $976M | Buy |
23,498,604
+225,197
| +1% | +$10.1M | 0.71% | 40 |
|
|
2024
Q1 | $1.26B | Sell |
23,273,407
-260,971
| -1% | -$13.3M | 0.94% | 30 |
|
|
2023
Q4 | $1.21B | Buy |
23,534,378
+2,998,228
| +15% | +$157M | 0.96% | 32 |
|
|
2023
Q3 | $1.19B | Sell |
20,536,150
-410,895
| -2% | -$25.2M | 1.01% | 33 |
|
|
2023
Q2 | $1.34B | Sell |
20,947,045
-567,360
| -3% | -$38M | 1.12% | 24 |
|
|
2023
Q1 | $1.49B | Sell |
21,514,405
-342,160
| -2% | -$24.1M | 1.3% | 22 |
|
|
2022
Q4 | $1.57B | Sell |
21,856,565
-281,110
| -1% | -$21.2M | 1.44% | 18 |
|
|
2022
Q3 | $1.57B | Sell |
22,137,675
-74,030
| -0.3% | -$5.37M | 1.52% | 17 |
|
|
2022
Q2 | $1.71B | Sell |
22,211,705
-158,670
| -0.7% | -$12.1M | 1.53% | 19 |
|
|
2022
Q1 | $1.63B | Buy |
22,370,375
+255,920
| +1% | +$17.2M | 1.23% | 21 |
|
|
2021
Q4 | $1.38B | Buy |
22,114,455
+3,195,680
| +17% | +$187M | 0.95% | 29 |
|
|
2021
Q3 | $1.12B | Sell |
18,918,775
-9,450
| -0% | -$622K | 0.79% | 37 |
|
|
2021
Q2 | $1.26B | Sell |
18,928,225
-308,740
| -2% | -$20.1M | 0.85% | 34 |
|
|
2021
Q1 | $1.21B | Sell |
19,236,965
-303,483
| -2% | -$18.9M | 0.85% | 36 |
|
|
2020
Q4 | $1.21B | Sell |
19,540,448
-423,277
| -2% | -$26M | 0.9% | 33 |
|
|
2020
Q3 | $1.2B | Sell |
19,963,725
-660,070
| -3% | -$39.7M | 0.99% | 28 |
|
|
2020
Q2 | $1.21B | Sell |
20,623,795
-1,097,360
| -5% | -$65.6M | 1.04% | 25 |
|
|
2020
Q1 | $1.21B | Sell |
21,721,155
-1,100,700
| -5% | -$67.3M | 1.19% | 25 |
|
|
2019
Q4 | $1.46B | Buy |
22,821,855
+426,180
| +2% | +$24.4M | 1.06% | 27 |
|
|
2019
Q3 | $1.14B | Buy |
22,395,675
+632,340
| +3% | +$29.7M | 0.91% | 32 |
|
|
2019
Q2 | $987M | Buy |
21,763,335
+14,140
| +0.1% | +$659K | 0.73% | 44 |
|
|
2019
Q1 | $1.04B | Buy |
21,749,195
+3,171,821
| +17% | +$158M | 0.76% | 41 |
|
|
2018
Q4 | $966M | Sell |
18,577,374
-329,320
| -2% | -$17.7M | 0.78% | 40 |
|
|
2018
Q3 | $1.17B | Buy |
18,906,694
+862,900
| +5% | +$51.2M | 0.79% | 41 |
|
|
2018
Q2 | $999M | Buy |
18,043,794
+1,612,844
| +10% | +$87.1M | 0.74% | 44 |
|
|
2018
Q1 | $1.04B | Buy |
16,430,950
+9,873,372
| +151% | +$635M | 0.78% | 41 |
|
|
2017
Q4 | $402M | Buy |
6,557,578
+182,678
| +3% | +$11.4M | 0.31% | 77 |
|
|
2017
Q3 | $406M | Buy |
6,374,900
+59,900
| +0.9% | +$3.5M | 0.34% | 74 |
|
|
2017
Q2 | $352M | Buy |
6,315,000
+4,542,100
| +256% | +$247M | 0.3% | 77 |
|
|
2017
Q1 | $96.4M | Buy |
+1,772,900
| New | +$97.2M | 0.09% | 134 |
|
Other funds holding BMY
Primecap Management's BMY Position: Q2 2026 in Review
Primecap Management reduced its Bristol-Myers Squibb (BMY) stake by 0.25% in Q2 2026, selling an estimated $3.52M and leaving 24,923,900 shares worth $1.44B. The position accounts for 0.85% of the portfolio, ranked #25.
Primecap Management first reported a position in BMY in Q1 2017 and has held it in 38 quarters since. The position peaked at $1.71B in Q2 2022. 2,506 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Primecap Management held 24,923,900 shares of Bristol-Myers Squibb worth $1.44B as of Q2 2026.
- Primecap Management sold 61,249 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.52M.
- Bristol-Myers Squibb made up 0.85% of Primecap Management's portfolio in Q2 2026, its #25 holding.
- Primecap Management first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 38 quarters since.
- Primecap Management's Bristol-Myers Squibb position peaked at $1.71B in Q2 2022.
- 2,506 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Primecap Management's 13F filing for Q2 2026, filed 14 Aug 2026.